Table 1.
Baseline data by treatment group
| Lifestyle/medical management (n = 59) | RYGB (n = 60) | |
|---|---|---|
| Demographics | ||
| Age (years) | 49 (8) | 49 (9) |
| Female, n (%) | 34 (57) | 38 (63) |
| Race/ethnicity, n (%) | ||
| Non-Hispanic white | 30 (50) | 33 (55) |
| East Asian | 17 (28) | 16 (27) |
| Non-Hispanic black | 6 (10) | 5 (8) |
| Hispanic | 4 (7) | 4 (7) |
| Native American | 1 (2) | 2 (3) |
| Other | 2 (3) | 0 (0) |
| General medical information | ||
| BMI (kg/m2) | 34.3 (3.1) | 34.9 (3.0) |
| BMI 30.0–34.9 kg/m2, n (%) | 35 (58) | 36 (60) |
| Waist circumference (cm) | 113 (12) | 114 (10) |
| SBP (mmHg) | 132 (14) | 127 (15) |
| DBP (mmHg) | 79 (10) | 78 (12) |
| Years since diabetes diagnosis | 9.1 (5.7) | 8.9 (6.1) |
| Laboratory values (serum) | ||
| HbA1c (%) | 9.6 (1.2) | 9.6 (1.0) |
| LDL cholesterol (mg/dL) | 105 (43) | 103 (36) |
| HDL cholesterol (mg/dL) | 42 (9) | 41 (1) |
| Triglycerides (mg/dL) | 197 (82) | 187 (79) |
| Total cholesterol (mg/dL) | 189 (46) | 182 (39) |
| Creatinine (mg/dL) | 0.79 (0.19) | 0.81 (0.20) |
| Fasting C-peptide (ng/mL) | 3.0 (1.4) | 2.7 (1.4) |
| Postmeal C-peptide (ng/mL) | 4.7 (2.1) | 4.3 (2.0) |
| Fasting glucose (mg/dL) | 206 (52) | 214 (57) |
| Medicines | ||
| Taking insulin, n (%) | 25 (42) | 37 (62) |
| Taking other glycemic medicines, n (%) | 56 (95) | 52 (87) |
| Taking dyslipidemia medicines, n (%) | 40 (68) | 39 (65) |
| Taking blood pressure medicines, n (%) | 43 (73) | 41 (68) |
| Number of medications for control of glycemia, dyslipidemia, and blood pressure | 4.4 (1.5) | 4.1 (1.9) |
Data are means (SD) unless otherwise indicated. RYGB, Roux-en-Y gastric bypass.